RenuTend contains tenogennic primed equine allogeneic peripheral blood-derived mesenchymal stem cells. It comes as a suspension for injection for use in horses. The intended use is to promote tissue healing mechanisms in ligaments and tendons, in particular improving the healing of tendon and suspensory ligament injuries.
The product has only just received a positive opinion for initial marketing on the 16th February 2022 so it will be a while before it is released onto the veterinary market. We will provide more information on the product when it becomes available.
If you have any specific questions regarding RenuTend please contact our customer services on [email protected].
Written by: Dr. Nick Garside BVetMed MRCVS
